To compare vapor tunnel (VT) and virtual basket (VB) tools to reduce retropulsion in the treatment of proximal ureteral stones. Patients with a single proximal ureteral stone were randomly assigned to holmium laser lithotripsy with the use of VT (Group A) or VB (Group B) tool. The 150W holmium:YAG cyber Ho generator was used. We compared operative time, dusting time, need for flexible ureteroscopy due to stone push-up and occurrence of ureteral lesions. The stone-free rate (SFR) and the occurrence of postoperative ureteral strictures were assessed. 186 patients were treated, of which 92 with the VT (49.5

Prostate cancer (РСа), being one of the leading causes of cancer mortality in men in Russia and in a number of other countries of the world, remains an urgent problem for modern oncourology, and the choice of surgical method is an important task for a surgeon. Such a pronounced interest in robot-assisted radical prostatectomy (RARP) in patients is driven by good tolerance and effectiveness of these surgical interventions, despite the fact that radical prostatectomy is considered to be the "gold standard" for treatment of patients with clinically localized РСа with regard to European Association of Urology data. The long-term oncological and functional results and the quality of life of patients after RARP deserve close attention and thorough study. According to the data presented in this article, it is obvious that RARP is the preferred method for surgical treatment of РСа, since oncological and functional results in the long-term follow-up are comparable to the results after radical prostatectomy, and according to some authors, these results are superior to the results of radical prostatectomy. The results of the study will allow to continue further introduction of RARP into clinical practice and its popularization as a method of surgical treatment of patients with localized PCa, which will reduce the length of hospital stay of patients, accelerate their medical and social rehabilitation, and improve the quality of medical care.The amount of data on the study of distant oncological and functional results of RARP as well as its superiority over other treatment methods is limited in medical literature, which prompted us to conduct our own research. Currently the urological clinic of the A.I. Evdokimov Moscow State University of Medicine and Dentistry continues work aimed at studying the longterm results of RARP in the first patients in Russia.

Since the first cases of coronavirus disease were detected in Wuhan (Hubei Province, China) in December 2019, the spread distribution of COVID-19 has expanded so much that the World Health Organization declared COVID-19 a pandemic. The most common symptoms of coronavirus infection are fever (85-90%), cough (65-70%), general weakness (35-40%), shortness of breath or feeling short of breath (15-20%); less common symptoms such as myalgia, headaches, sore throat and chills (10-15%). Currently, cases of infection are recorded in almost all countries of the world, there is a daily increase in the number of infected by an average of 100,000, and the death toll by average estimates is over 3,000,000. At present time, the "leading" position in the number of cases of COVID-19 detected belongs to the United States, in which over the entire observation period, more than 32,000,000 thousand cases were recorded. Another badly affected region is Europe, in which more than 43,000,000 thousand cases were recorded. The rapid growth in the number of newly diagnosed cases of COVID-19 dictates the need to search for optimal ways of providing medical care. It is obvious that inpatient practice carrying high risk of infection for patients as well as for medical stuff. Moreover, postoperative mortality rate in infected patients may be as high as 20%. Since the pandemic onset many authors and societies have provided recommendations on how the risk of infection during inpatient practice should be reduced. This article discusses the options for providing inpatient care to urological patients in a pandemic of the coronary viral infection COVID-19.